News RNA specialist Ribo files $205m IPO in Hong Kong Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.
News BMS, J&J give up on milvexian for acute coronary syndrome BMS and J&J call time on oral anticoagulant milvexian in acute coronary syndrome, but are still running trials in atrial fibrillation and stroke.
News AHA: MSD's oral PCSK9 matches injectables MSD closes on filing for enlicitide, a PCSK9 inhibitor that could offer the efficacy of injectables with the ease of a once-daily pill.
News George's triple therapy for hypertension hits mark in stroke George Medicines' new triple pill for hypertension delivers a much-needed win in a phase 3 trial in haemorrhagic stroke.
News AZ chalks up another positive trial for hypertension drug AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filing later this year.
News Novartis pens $5.2bn cardiovascular partnership with Argo Novartis is paying $160m upfront to activate an expanded R&D alliance with China's Argo Biopharma covering multiple cardiovascular disease drugs.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
